Pulmonary Department, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
J Thorac Dis. 2013 Feb;5(1):74-9. doi: 10.3978/j.issn.2072-1439.2013.01.03.
Lymphangioleiomyomatosis is a rare slowly progressive lung disease that affects almost exclusively young women of reproductive age. It occurs sporadically or in association with Tuberous Sclerosis Complex. LAM is characterized by cystic remodeling of the lung parenchyma, due to proliferation of abnormal smooth muscle-like LAM cells and presence of extra pulmonary manifestations such as lymphadenopathy, angiomyolipomas and abdominal lymphangioleiomyomas. The most common clinical manifestations are progressive dyspnea on exertion, pneumothorax and chylous effusions. Currently there is no curative treatment for the disease, but the ongoing study of the genetic and molecular pathways implicated in the pathogenesis of the disease could lead to targeted therapy.
淋巴管平滑肌瘤病是一种罕见的、进展缓慢的肺部疾病,几乎仅影响育龄期年轻女性。它可散发发生或与结节性硬化症相关。LAM 的特征是肺实质的囊性重塑,这是由于异常平滑肌样 LAM 细胞的增殖和肺外表现的存在,如淋巴结病、血管平滑肌脂肪瘤和腹部淋巴管平滑肌瘤病。最常见的临床表现是进行性劳力性呼吸困难、气胸和乳糜胸。目前,该病尚无治愈方法,但对发病机制中涉及的遗传和分子途径的持续研究可能会导致靶向治疗。